Evaluation of progression-free survival (PFS) and one-year (1y) survival as surrogate endpoints (SE) in previously treated advanced non-small cell lung cancer (adNSCLC) in the era of immuno-oncology (IO)

被引：0
|
作者：
Zhao, S. [1 ]
Zhang, Z. [1 ]
Zhou, T. [1 ]
Zhang, Y. [1 ]
Zhang, L. [1 ]
机构：
[1] Sun Yat Sen Univ, Ctr Canc, Med Oncol, Guangzhou, Guangdong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1477P
引用
收藏
页码：535 / 535
页数：1
相关论文
共 50 条
  • [1] Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer
    Zhao, Shen
    Zhang, Zhonghan
    Zhang, Yaxiong
    Hong, Shaodong
    Zhou, Ting
    Yang, Yunpeng
    Fang, Wenfeng
    Zhao, Hongyun
    Zhang, Li
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (11) : 2854 - 2866
  • [2] Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
    Akamatsu, Hiroaki
    Mori, Keita
    Naito, Tateaki
    Imai, Hisao
    Ono, Akira
    Shukuya, Takehito
    Taira, Tetsuhiko
    Kenmotsu, Hirotsugu
    Murakami, Haruyasu
    Endo, Masahiro
    Harada, Hideyuki
    Takahashi, Toshiaki
    Yamamoto, Nobuyuki
    [J]. BMC CANCER, 2014, 14
  • [3] Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
    Hiroaki Akamatsu
    Keita Mori
    Tateaki Naito
    Hisao Imai
    Akira Ono
    Takehito Shukuya
    Tetsuhiko Taira
    Hirotsugu Kenmotsu
    Haruyasu Murakami
    Masahiro Endo
    Hideyuki Harada
    Toshiaki Takahashi
    Nobuyuki Yamamoto
    [J]. BMC Cancer, 14
  • [4] Progression-free survival (PFS) and overall survival (OS) in phase HI trials of systemic chemotherapy in advanced non-small cell lung cancer (NSCLC).
    Hotta, K.
    Kiura, K.
    Takigawa, N.
    Tabata, M.
    Fujiwara, Y.
    Tanimoto, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] OVERVIEW OF PRIMARY ENDPOINTS, PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) FOR NON-SMALL CELL LUNG CANCER (NSCLC): THEIR VALUE IN TREATMENT DECISIONS AND PATIENT CARE
    Heron, Louise
    Chouaid, Christos
    Vergnenegre, Alain
    Bischoff, Helge
    Walzer, Stefan
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1447 - S1448
  • [6] OVERVIEW OF PRIMARY ENDPOINTS, PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) FOR NON-SMALL CELL LUNG CANCER (NSCLC): THEIR VALUE IN TREATMENT DECISIONS AND PATIENT CARE
    Heron, L.
    De Castro Carpeno, J.
    Chouaid, C.
    Vergnenegre, A.
    Bischoff, H. G.
    Walzer, S.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A177 - A178
  • [7] VALUE OF PROGRESSION-FREE SURVIVAL (PFS) IN REFRACTORY NON-SMALL CELL LUNG CANCER (NSCLC): AN EXPLORATORY MODELING ANALYSIS
    Ferrufino, C. P.
    Foley, D.
    Trochlil, K.
    Munakata, J.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A447 - A447
  • [8] Pembrolizumab Plus Docetaxel Increases Progression-Free Survival Compared with Docetaxel Alone in Previously Treated Advanced Non-Small Cell Lung Cancer Patients
    Arrieta, O. G.
    Barron, F.
    Carmona, A.
    Ramirez-Tirado, L.
    Zatarain Barron, Z. L.
    Cardona, A. F.
    Bautista, Y.
    Aldaco, F.
    Lazaro, M.
    Baez, R.
    Gerson, R.
    Blanco, C.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S291 - S291
  • [9] THE VALIDITY OF OBJECTIVE RESPONSE RATE AS A SURROGATE FOR PROGRESSION-FREE AND OVERALL SURVIVAL IN THE EVALUATION OF FIRST LINE CHEMOTHERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER
    Goring, S. M.
    Briggs, A.
    Penrod, J. R.
    Fan, S.
    Waser, N.
    Thompson, J.
    Wilson, J. B.
    Wang, S.
    Korytowsky, B.
    Chirita, O.
    Hertel, N.
    Yuan, Y.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A421 - A421
  • [10] Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab
    Taniguchi, Yoshihiko
    Tamiya, Akihiro
    Isa, Syun-Ichi
    Nakahama, Kenji
    Okishio, Kyoichi
    Shiroyama, Takayuki
    Suzuki, Hidekazu
    Inoue, Takako
    Tamiya, Motohiro
    Hirashima, Tomonori
    Imamura, Fumio
    Atagi, Shinji
    [J]. ANTICANCER RESEARCH, 2017, 37 (10) : 5857 - 5862
12345